Your innovations should have a chance to make a difference
One barrier to the successful commercialization of innovations arising from Ontario’s life sciences sector is the scarcity of funding to advance breakthroughs with market potential. FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.
Prospects Oncology Fund
FACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First investment strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding ranges between $50,000 and $200,000.
Compass Rose Oncology Fund
FACIT’s Compass Rose Fund helps Ontario’s cancer research innovators, arising from both public and private sectors, realize the commercial possibilities of their inventions by supporting early stage development projects. The Compass Rose Fund anchors and scales biotechs and attracts investment to Ontario, supporting the province’s competitive position as a destination for biotechnology.
Falcons’ Fortunes
Falcons’ Fortunes is the only pitch competition specifically for Ontario-made breakthrough cancer innovations. Selected entrepreneurs and scientists compete for the $100,000 Ernsting Entrepreneurship Award. Falcons’ Fortunes is FACIT’s premier event to celebrate and grow the entrepreneurial spirit within the cancer research community.
WeSEED PROGRAM
The Women’s Synergistic Entrepreneurship and Economic Development (WeSEED) program leverages the combined complementary capital, expertise and resources of OBIO® and FACIT. The resulting synergies provide a continuum of seamless support and lower barriers faced by women STEM leaders in accessing business training, advisory resources, networks and venture funding.
“The seed and follow-on capital investment from FACIT and the support on the Board of Directors were critically important to Fusion ultimately getting financed and its lead molecule reaching patients in our first clinical trial.”
Dr. John Valliant, CEO, Fusion Pharmaceuticals
“With help from OICR and FACIT together we have been able to achieve commercial success for our research far beyond what we could have done without a big picture, collaborative approach”
Dr. John Bell, Ottawa Hospital Research Institute, Scientist and Co-Founder, Turnstone Biologics